---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-037627"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:22:35.154058+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acrivon reports Q4 2023 net loss of $19.3M; cash runway into Q4 2025

## Summary
- Net loss Q4 2023 $19.3M, full year $60.4M; R&D expenses $15.5M/$46.0M.
- Cash, equivalents and marketable securities $127.5M at Dec 31, 2023; funds operations into Q4 2025.
- ACR-368 Phase 2 trial enrolling; Phase 1b combo with gemcitabine completed; ACR-2316 IND studies advancing.
- Two abstracts accepted for AACR 2024 on ACR-2316 and ACR-368 resistance mechanism.
- Appointed Jean-Marie Cuillerot as CMO; added two new board members.

## SEC filing metadata
- accession: 0000950170-24-037627
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017024037627/0000950170-24-037627-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017024037627/acrv-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-037627
- JSON: https://secwatch.observer/filing/0000950170-24-037627.json
- Plain text: https://secwatch.observer/filing/0000950170-24-037627.txt

## Key facts
- Earnings Releases
  Acrivon Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income $19.3 million and $60.4 million, respectively.
  - Period: fourth quarter and full year ended December 31, 2023
  - Net income: $19.3 million and $60.4 million, respectively
  - Result: reported results
  source text: Net loss for the quarter and full year ended December 31, 2023 was $19.3 million and $60.4 million, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000095017024037627/0000950170-24-037627-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.